Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591193 | 0.91 | ALK (0.31) | ALKINSRIGF1RALDH1A1LMNA | |
| SCHEMBL589444 | 0.90 | ALK (0.32) | ALKINSRIGF1RALDH1A1LMNA | |
| SCHEMBL589707 | 0.89 | CACNA1B (0.34) | ALKINSRIGF1RALDH1A1LMNA | |
| SCHEMBL589465 | 0.85 | TRPV4 (0.33) | ALKINSRIGF1RALDH1A1MAPT | |
| SCHEMBL592098 | 0.85 | ALK (0.31) | ALKINSRIGF1RALDH1A1MAPT | |
| SCHEMBL592571 | 0.83 | TRPM8 (0.32) | LMNAMAPT | |
| SCHEMBL590369 | 0.82 | ALK (0.37) | ALKINSRIGF1RMAPT | |
| SCHEMBL590446 | 0.82 | ABCC9 (0.32) | ALKALDH1A1LMNAMAPTHSD17B10 | |
| SCHEMBL591873 | 0.81 | KDM4E (0.34) | ALKINSRIGF1RALDH1A1 | |
| SCHEMBL591241 | 0.81 | BDKRB1 (0.34) | ALDH1A1LMNAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | ALK 420/4885INSR 400/4885IGF1R 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.